Restore Medical, a clinical-stage MedTech company developing transcatheter therapies for heart failure, has announced the successful closing of a 23 million USD Series B financing round. The round was co-led by Pitango HealthTech and a global strategic healthcare partner, alongside the European Innovation Council (EIC) Fund, and continued support from existing investors including Peregrine Ventures, which has supported the company since its inception, and another strategic partner.
Related: Kardium raises $250m to support PFA system launch
The round will fund the completion of Restore Medical’s ongoing European feasibility study, which has demonstrated promising long-term safety and efficacy data, including meaningful improvements in ventricular reverse remodelling, haemodynamic performance, and patient functional capacity. The investment will also support the launch of a U.S.-based clinical study, following the Breakthrough Device Designation granted by the FDA in 2024.
Restore Medical says its ‘unique’ transcatheter approach introduces a new minimally invasive therapeutic option for heart failure patients who have limited effective treatments today.
“We are proud to have the support of such a strong and diverse group of partners, including two global strategic investors, the European Innovation Council Fund, and leading VCs such as Peregrine Ventures and Pitango HealthTech,” said Gilad Marom, CEO of Restore Medical. “Their confidence in our vision, team, and technology is a powerful endorsement. With encouraging clinical data and FDA Breakthrough Device designation, we are well positioned to advance this technology toward making a meaningful impact for patients worldwide.”
Jonathan Glazer, MD. Partner at Pitango HealthTech added: “Heart failure remains one of the greatest unmet needs in medicine, both clinically and economically. As a clinician and executive in healthcare systems, I have seen firsthand how urgent the need is for better solutions. Restore Medical’s innovative approach, compelling early data, and exceptional leadership made it a clear choice for us to co-lead this round.”
